Drug Database
KE

ketoprofen (Ketopatch / ketoprofen, Pacific / Ketotop patch)

✓ Approved

Aestura · PTGS1 · Small Molecule

What is ketoprofen?

ketoprofen is a small molecule developed by Aestura. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesKetopatch, ketoprofen, Pacific, Ketotop patch
CompanyAestura
Drug ClassSmall Molecule
Molecular TargetPTGS1, PTGS2
RouteTransdermal
StatusApproved

Mechanism of Action

Molecular Targets

ketoprofen acts on 2 molecular targets:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ketoprofen is developed for 6 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsEpicondylitis✓ Approved
Hepatobiliary disordersHepatitis✓ Approved
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved

+1 more indication available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedBiology of sex differences2026-10-21

Unraveling circRNAs and ceRNA regulatory networks underlying sex-specific gametogenesis impairment in triploid Pacific oysters (Crassostrea gigas).

Guo Lang L, Wang Huihui H, Yu Hong H, Li Qi Q

In the Pacific oyster Crassostrea gigas, triploidization-a well-established technique for generating sterile organisms-provides a promising model to study reproductive dysfunction, as it causes severe and sex-specific impairments in gametogenesis. Specifically, triploid males produce abundant spermatocytes and spermatids but fail to generate mature spermatozoa, while oogenesis in triploid females presents a more complex and heterogeneous picture. The molecular basis for this differential gametogenesis impairment, however, is not fully understood. To investigate the roles of circRNA and ceRNA networks in the sex-specific gametogenesis impairment of triploid oysters, gonadal circRNAs were identified and their expression was profiled from whole transcriptome data of diploid and triploid oysters. Differentially expressed circRNAs were then subjected to functional enrichment analysis. Competitive endogenous RNA (ceRNA) networks were constructed from the interactions of differentially expressed RNAs. Key candidate genes implicated in gametogenesis impairment were then identified and characterized through integrated bulk and single-nucleus RNA-seq analyses. Differential expression analysis revealed substantial alterations in circRNAs expression between diploid and triploid gonads. Functional enrichment of circRNA source genes implicated global metabolic and cell proliferation pathways associated with oogenesis impairment, while it implicated lipid/steroid metabolism, cell proliferation, and apoptosis pathways associated with spermatogenesis disruption in triploid oysters. Sex-specific ceRNA networks were constructed for oogenesis and spermatogenesis, revealing extensive regulatory rewiring in triploid gonads. Analysis of bulk and single-nucleus RNA-seq data identified key candidate genes within these ceRNA networks. Specifically, upregulation of FoxG1, Sox11, Cyp2J6, and Tra2A in somatic cells, combined with downregulation of Uhrf1, Ccna2, Sox2, and Bre1 in germ cells, was implicated in oogenesis impairment of triploids. Similarly, the ceRNA-mediated suppression of Iqch, Ccdc173, Srebp1, and Gtpbp2 was linked to disrupted spermatogenesis. These findings highlight that circRNA-mediated ceRNA dysregulation is potentially associated with gametogenesis impairment in triploid oysters, and offer novel insights into post-transcriptional regulatory mechanisms underlying molluscan reproduction.

PubMedJournal of internal medicine2026-10-21

Interacting climatic, environmental, biologic and socio-economic drivers of the global dengue expansion.

Semenza Jan C JC

Dengue is the most rapidly expanding mosquito-borne viral disease worldwide. The worst year on record was 2024, with over 100 countries reporting 14.4 million cases and over 11,000 deaths. Since then, and up to August 2026, another 7.4 million cases and over 5000 deaths have been reported. The region of the Americas was impacted the most, followed by South-East Asia and the Western Pacific. Both the spread of dengue viruses (DENV) and their primary vectors, Aedes aegypti and Aedes albopictus, are driven by several factors. Globalization has accelerated vector dispersal, particularly through international trade and transportation networks. The movement of desiccation-resistant eggs in used-vehicle tyres and the inadvertent transport of adult mosquitoes via trucks and passenger vehicles have enabled the establishment of vector populations in previously uncolonized regions. Human mobility and unplanned urbanization further contribute to dengue emergence by introducing DENV into susceptible populations where competent vectors circulate. Climate change has enhanced dengue transmission potential by altering temperature and rainfall patterns that influence mosquito survival, reproduction, biting behaviour and viral replication. Containing or even reversing this global dengue expansion will require a complementary set of interventions that rely on proven and novel control strategies, including sterile insect techniques, Wolbachia-infected mosquitoes, virus-resistant mosquito strains through CRISPR-Cas9 gene drive, vaccines, antiviral drug prophylaxis and urban interventions that eliminate Aedes habitats. Building climate-resilient urban environments through sustainable development to minimize the urban heat island effect and advancing climate-informed early warning systems are long-term strategies for effective dengue control.

PubMedFrontiers in public health2026-10-20

Anticipating El Niño-related health risks in Latin America and the Caribbean: from climate information to public health preparedness.

Ortiz-Prado Esteban E, Vasconez-Gonzalez Jorge J, Zalakeviciute Rasa R, Izquierdo-Condoy Juan S JS

El Niño is a recurrent mode of tropical Pacific climate variability with major public health implications for Latin America and the Caribbean. Its development is partly driven by the Bjerknes feedback, a coupled ocean-atmosphere process in which weakened equatorial trade winds reduce coastal upwelling and allow warm surface waters to shift eastward. Warming of the central and eastern tropical Pacific can reshape regional rainfall and temperature patterns, increasing the likelihood of floods, droughts, wildfires, food-system disruption, and health-service interruption in locations with established ENSO teleconnections. This narrative review synthesizes evidence on the environmental and health pathways through which El Niño may affect populations in Latin America and the Caribbean. We distinguish evidence directly linking health outcomes to ENSO or Coastal El Niño from evidence derived from floods, droughts, wildfires, and other hydrometeorological disasters without formal attribution to ENSO. The latter is used to characterize plausible health pathways and preparedness needs rather than ENSO-specific causal effects. Potential consequences include immediate mortality and injury, waterborne and vector-borne infections, disruption of chronic disease care, food insecurity, undernutrition, toxic exposures, psychological distress, and prolonged health-system burden. The timing and persistence of these effects are context-dependent; preparedness and response priorities are therefore organized by operational needs rather than fixed post-event intervals. As of August 2026, authoritative forecasts indicated that El Niño was present and strengthening, providing a current illustration of why anticipatory preparedness is necessary while not guaranteeing any specific regional impact. Early warning, flood-risk mapping, water, sanitation, and hygiene interventions, epidemiological and entomological surveillance, continuity of health services, and community-centered risk communication should therefore be adapted to local forecasts, vulnerabilities, and surveillance data.

PubMedBMC neurology2026-10-20

Trends in hospitalizations for non-traumatic subarachnoid hemorrhage in the United States: 2012-2020.

Geraghty Joseph R JR, Law Connor A CA, Magee Rogan G RG, Hamedani Ali G AG et al.

Although non-traumatic subarachnoid hemorrhage (SAH) remains an important cause of death and disability worldwide, contemporary research on hospitalization trends over time and across demographic groups remains scarce. We performed a cross-sectional study of U.S. SAH hospitalizations from 2012 to 2020 using data from the National Inpatient Sample. SAH-related hospital discharges were identified using diagnostic codes from the International Classification of Disease, Ninth and Tenth Revisions (ICD-9/10). Incidence per 100,000 hospitalizations was calculated (2012-2020), pre- and post- the ICD-9 to ICD-10 transition (2012-2015; 2016-2020), and yearly among all hospitalizations and in subgroups defined by patient age, sex, race and ethnicity, and hospital region. Linear regression models were used to estimate change in incidence over time (separately for 2012-2015 and 2016-2020). Estimates are reported per 100,000 hospitalizations. From 2012 to 2020, the overall incidence of SAH hospitalization was 88.9 per 100,000 hospital discharges (95%CI = 88.6,89.3). We observed a discontinuity in incidence prior to (72.9, 95%CI = 72.5,73.5) and after (102.1, 95%CI = 101.6,102.5) the transition to ICD-10. From 2012 to 2015 the annual incidence of non-traumatic SAH hospitalization was relatively stable (3.6, 95%CI=-0.1,7.3), but higher among males, individuals of White, Black, and Asian or Pacific Islander race, and in the Midwest. From 2016 to 2020, the annual incidence of non-traumatic SAH hospitalization decreased (-2.9, 95%CI=-3.4,-2.3). This finding was largely consistent across age, sex, race or ethnicity, and region subgroups, with the largest decrease in incidence observed for aged ≥ 75 years (-8.4, 95%CI=-12.7,-4.2) and for individuals of Asian or Pacific Islander race (-11.3, 95%CI=-20.2,-2.4). Although the incidence of non-traumatic SAH hospitalization remained stable from 2012 to 2015 and decreased from 2016 to 2020, our analysis suggests persistent differences in the risk of SAH hospitalization across subgroups defined by age, sex, and race/ethnicity.

PubMedEnvironmental science & technology2026-10-20

Neglecting Changes in Salinity and Tidal Range Overstates Projected Increases in Greenhouse Gas Emissions from Mangrove Sediments.

Zheng Siyi S, Fu Chuancheng C, Bao Tao T, Lin Yajing Y et al.

Mangroves are important coastal blue carbon ecosystems, but future sediment GHG emissions remain uncertain because global projections have largely emphasized atmospheric climate drivers, with less attention to coastal hydrology, particularly sea-surface salinity and tidal range. Here, we compiled 810 sediment GHG flux measurements from 294 mangrove sites worldwide and used machine learning to project emissions to 2050, distinguishing climate-driven changes from the additional effects of projected shifts in sea-surface salinity and tidal range. We estimate a mangrove sediment GHG budget of ∼194 Tg CO2e yr-1 across reliably predicted mangrove areas worldwide around 2020. By 2050 under SSP5-8.5, projected changes in salinity and tidal range counteracted 41% of the climate-driven increase in emissions globally, with comparable offset effects among CO2, CH4, and N2O. Hydrological offset effects were strongest at 10-20° latitude in both hemispheres and weakened toward the equator and higher latitudes. Regionally, hydrological offset effects were greatest in East Africa, whereas the Indo-Pacific showed the largest absolute hydrology-driven reductions in emission budgets, largely owing to its extensive mangrove area. These findings highlight the importance of incorporating sea-surface salinity and tidal range into future projections of mangrove sediment GHG emissions under global change.

PubMedEwha medical journal2026-10-20

Global, regional, and national burden of motor neuron diseases, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

Park Jung-Hyun JH, Yon Dong Keon DK, Kim Min-Seo MS, Chang Yoonkyung Y et al.

Healthcare planning and resource allocation require accurate estimates of the burden of motor neuron diseases (MNDs). This study evaluated the global impact of MNDs from 1990 to 2021 as part of the Global Burden of Disease (GBD) Study 2021. GBD 2021 data were used to assess the global burden of MNDs from 1990 to 2021 in terms of prevalence, incidence, disability-adjusted life years (DALYs), and deaths. The relationship between MND burden and the Socio-demographic Index (SDI) was also examined. Globally, MNDs accounted for 272,732 prevalent cases (95% uncertainty interval [UI], 236,195-313,676), 64,178 incident cases (95% UI, 58,506-70,270), 1,040,566 DALYs (95% UI, 963,064-1,123,956), and 39,082 deaths (95% UI, 35,757-42,433) in 2021. The corresponding age-standardized rates per 100,000 people were 3.31 (95% UI, 2.86-3.80) for prevalence, 0.46 (95% UI, 0.42-0.49) for mortality, and 12.17 (95% UI, 11.24-13.15) for DALYs. From 1990 to 2021, the numbers of prevalent and incident cases increased, but their age-standardized rates decreased by 1.36% and 4.69%, respectively. By contrast, the age-standardized mortality rate increased by 19.84%. MND burden was generally higher in regions with a high SDI, although rates in high-income Asia Pacific were relatively low compared with those in regions with similar SDI values. From 1990 to 2021, the absolute burden of MNDs increased, age-standardized prevalence and incidence rates declined slightly, and mortality-related burden increased. These trends underscore the need for evidence-based national and global healthcare planning. Geographic variation in MND burden may reflect regional differences in the roles of sociodemographic and genetic factors.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ketoprofen